NeoGenomics, Inc is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. NeoGenomics employs 1,700 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in NeoGenomics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NEO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
NeoGenomics stock price (NASDAQ: NEO)Use our graph to track the performance of NEO stocks over time.
NeoGenomics shares at a glance
|Latest market close||$41.03|
|52-week range||$34.18 - $61.57|
|50-day moving average||$44.46|
|200-day moving average||$47.43|
|Wall St. target price||$57.27|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.04|
Buy NeoGenomics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy NeoGenomics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NeoGenomics price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-6.64%|
|3 months (2021-05-03)||-13.78%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Is NeoGenomics under- or over-valued?
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's PEG ratio
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.8 million.
The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$454 million|
|Gross profit TTM||$186.4 million|
|Return on assets TTM||-0.81%|
|Return on equity TTM||-1.63%|
|Market capitalisation||$5.6 billion|
TTM: trailing 12 months
Shorting NeoGenomics shares
There are currently 5.9 million NeoGenomics shares held short by investors – that's known as NeoGenomics's "short interest". This figure is 1% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting NeoGenomics shares can be evaluated.
NeoGenomics's "short interest ratio" (SIR)
NeoGenomics's "short interest ratio" (SIR) is the quantity of NeoGenomics shares currently shorted divided by the average quantity of NeoGenomics shares traded daily (recently around 598856.17977528). NeoGenomics's SIR currently stands at 9.79. In other words for every 100,000 NeoGenomics shares traded daily on the market, roughly 9790 shares are currently held short.
However NeoGenomics's short interest can also be evaluated against the total number of NeoGenomics shares, or, against the total number of tradable NeoGenomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeoGenomics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NeoGenomics shares in existence, roughly 50 shares are currently held short) or 0.0514% of the tradable shares (for every 100,000 tradable NeoGenomics shares, roughly 51 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeoGenomics.
Find out more about how you can short NeoGenomics stock.
NeoGenomics share dividends
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
Have NeoGenomics's shares ever split?
NeoGenomics's shares were split on a 1:100 basis on 15 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
NeoGenomics share price volatility
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $34.18 up to $61.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.6844. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Stocks similar to NeoGenomics
NeoGenomics in the news
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
Bear of the Day: NeoGenomics (NEO)
Friday’s Top Analyst Upgrades and Downgrades: AMD, Hartford Financial, Nokia, Pinterest, Riot Blockchain, T-Mobile and More
Frequently asked questionsWhat percentage of NeoGenomics is owned by insiders or institutions?
Currently 4.17% of NeoGenomics shares are held by insiders and 93.83% by institutions. How many people work for NeoGenomics?
Latest data suggests 1,700 work at NeoGenomics. When does the fiscal year end for NeoGenomics?
NeoGenomics's fiscal year ends in December. Where is NeoGenomics based?
NeoGenomics's address is: 12701 Commonwealth Drive, Fort Myers, FL, United States, 33913 What is NeoGenomics's ISIN number?
NeoGenomics's international securities identification number is: US64049M2098 What is NeoGenomics's CUSIP number?
NeoGenomics's Committee on Uniform Securities Identification Procedures number is: 64049M209
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert